Carperitide acetate hmoov, Kuj hu ua capecitabine acetate, lub npe lus Askiv yog Atrial Natriuretic Peptide (ANP) (1-28), tib neeg, porcine acetate. Nws yog cov tshuaj hormone peptide uas muaj 28 amino acids thiab yog ib qho analog ntawm atrial natriuretic peptide (ANP). Nws cov amino acid sequence yog Ser - Leu - Arg - Arg - Ser - Ser - Cys - Phe - Gly - Gly - Arg - Arg {{16} - As - Gly - Ala - Gln - Ser - Gly - Leu - Gly - Cys - Asn - Ser - Phe - Arg - Tyr. Ntawm lawv, cysteine residues ntawm txoj hauj lwm 7 (Cys7) thiab 23 (Cys23) tsim cov choj disulfide (Cys7-Cys23), uas ua rau cov molecule los tsim ib lub voj voog tshwj xeeb thiab tseem ceeb heev rau kev tswj hwm nws cov khoom lom. Lawv txwv qhov hloov pauv ntawm cov molecule, uas ua rau muaj kev sib haum xeeb tshwj xeeb uas ua rau muaj kev cuam tshuam tshwj xeeb rau lub hom phiaj receptor. Nws tuaj yeem inhibit qhov tso tawm ntawm endothelin-1, uas yog lub zog vasoconstrictor uas txhawb nqa vasoconstriction, nce peripheral vascular tsis kam, thiab thaum kawg nce ntshav siab. Hauv cov hlab plawv, kev tso tawm ntau dhau ntawm endothelin-1 tuaj yeem ua rau muaj qhov tshwm sim tsis zoo xws li vascular spasm thiab nce siab tom qab lub plawv, uas muaj kev cuam tshuam tsis zoo rau cov hlab plawv.
Peb Cov Khoom Muag Khoom






Carperitide Acetate COA



Carperitide acetate hmoovyog ib tug muaj zog vasoconstrictor peptide secreted los ntawm endothelial hlwb. Nws cov qauv molecular muaj 21 amino acid residues thiab ob daim ntawv cog lus disulfide, tsim kom muaj kev sib haum xeeb. ET-1 activates ETA receptors ntawm vacular du leeg hlwb, ua rau muaj kev nce hauv intracellular calcium ion concentration, ua rau vasoconstriction, nce peripheral vacular resistance, thiab thaum kawg kub siab. Tsis tas li ntawd, ET-1 tseem muaj cov haujlwm hauv qab no:
Cell Proliferation Thiab Differentiation: Stimulates proliferation ntawm vascularize smooth nqaij hlwb, fibroblasts, thiab lwm yam., thiab koom nyob rau hauv cov ntaub so ntswg kho thiab regeneration, tab sis yuav ua rau kom qhov txawv txav ntawm vascularize phab ntsa hauv atherosclerosis thiab lwm yam kab mob.
Neuroregulation: Raws li ib tug neurotransmitter los yog modulator, nws tswj cerebral vascularize nro, cerebral ntshav txaus, thiab neuroendocrine muaj nuj nqi.
Lub raum ua haujlwm: tswj cov kev tso tawm ntawm sodium thiab dej hauv lub raum tubules thiab cuam tshuam cov kua dej sib npaug.
Nyob rau hauv pathological tej yam kev mob, ntau ntau secretion ntawm ET-1 yog ze ze rau kub siab, plawv tsis ua hauj lwm, pulmonary hypertension, atherosclerosis thiab lwm yam kab mob. Piv txwv li, nyob rau hauv cov neeg mob uas muaj lub plawv tsis ua hauj lwm, plasma ET-1 qib tau nce siab, ua rau vasoconstriction ntau dhau, ua rau lub plawv dhia ntau dua, thiab ua rau lub voj voog tsis zoo.
Pharmacological mechanism
Nws yog ib qho khoom siv hluavtaws peptide ntawm 28 amino acids, uas muaj cov qauv zoo ib yam li atrial natriuretic peptide (ANP) thiab belongs rau tsev neeg natriuretic peptide. Nws cov core pharmacological mechanisms muaj xws li:
(1) Inhibition ntawm ET-1 secretion
Dose dependent inhibition: Acetate capreotide activates guanylate cyclase (GC{0}}A) receptor, nce intracellular theem ntawm guanylate (cGMP), yog li inhibiting gene transcription thiab protein synthesis ntawm ET-1. Piv txwv li, hauv npua aortic endothelial hlwb txhawb los ntawm angiotensin II (Ang II), acetate capecitabine txo qis kev tso tawm ntawm kev tiv thaiv kab mob ET-1, thaum cGMP qib nce.
Lub teeb liab txoj kev thaiv: Los ntawm cGMP protein kinase G (PKG) txoj kev, intracellular teeb liab transduction cuam tshuam nrog ET-1 secretion yog inhibited, txo qhov tso tawm ntawm ET-1 sab nraum lub cell.
(2) Diuretic thiab sodium excretion cuam tshuam

Kev tswj lub raum tubule: Capulet acetate khi rau GC-A receptor nyob rau saum npoo ntawm lub raum tubular epithelial hlwb, qhib lub cGMP PKG txoj hauv kev, inhibits sodium reabsorption nyob rau hauv cov tubules ze, txhim khu cov permeability ntawm kev sau duct, txhawb nqa sodium excretion thiab diuresis retention.
(3) Cov nyhuv vasodilatory
Direct vasodilation: Los ntawm kev nce qib cGMP, vascularize du cov nqaij ntshiv ncaj qha, peripheral vacular resistance txo, plawv tom qab txo qis, thiab cov zis tawm thiab cov ntaub so ntswg perfusion zoo tuaj.
Inhibition ntawm renin angiotensin aldosterone system (RAAS):
Txo qhov tso tawm ntawm angiotensin II thiab aldosterone: Capillary peptide acetate tuaj yeem cuam tshuam kev ua haujlwm ntawm RAAS, txo cov ntshav siab ntxiv, thiab txo cov dej thiab sodium retention.
Clinical tseem ceeb ntawm inhibiting ET-1 secretion
Kev kho mob plawv tsis ua hauj lwm:
Txhim kho hemodynamics:Carperitide acetatse tuaj yeem txo qis pulmonary capillary wedge siab (PCWP) thiab cov kab mob vascularize tsis kam, ua kom lub plawv dhia, thiab txo cov tsos mob ntawm lub plawv tsis ua hauj lwm los ntawm inhibiting ET-1 secretion thiab ncaj qha dilating cov hlab ntsha.
Tshem tawm cov kua dej: nws cov diuretic thiab natriuretic cuam tshuam tuaj yeem tshem tawm edema sai sai thiab txo qis hauv tsev kho mob. Piv txwv li, hauv kev sim tshuaj, kev kho mob nrog capecitabine acetate txo qis cov tsos mob xws li dyspnea thiab txhim kho lub neej zoo rau cov neeg mob.

Txo qhov kev pheej hmoo ntawm cov kab mob plawv:
Inhibition ntawm vascular remodeling: ET-1 yog ib qho tseem ceeb stimulating yam rau proliferation thiab migration ntawm vacular du leeg hlwb. Capotide acetate tuaj yeem tiv thaiv kev zais ntawm ET-1, txo cov phab ntsa vascular thickening thiab fibrosis, thiab ncua kev kawm ntawm atherosclerosis.
Txhim kho endothelial muaj nuj nqi: Kev tso tawm ntau dhau ntawm ET-1 tuaj yeem ua rau endothelial tsis ua haujlwm. Acetate capecitabine tuaj yeem rov ua haujlwm ntawm endothelial dependent vasodilation muaj nuj nqi thiab txo qhov tshwm sim ntawm cov hlab plawv los ntawm kev txo qis ET-1 qib.
Lub peev xwm ntawm kev sib xyaw ua ke:
Synergistic cuam tshuam nrog cov tswv cuab ntawm tsev neeg natriuretic peptide: Acetate capecitabine zoo ib yam li lwm cov tswv cuab ntawm tsev neeg natriuretic peptide, xws li hlwb natriuretic peptide (BNP), ob qho tib si uas muaj diuretic, natriuretic, thiab vasodilatory influences. Kev siv ua ke tuaj yeem txhim kho kev ua tau zoo, txo qhov ntau npaum li cas ntawm ib qho tshuaj, thiab txo qis kev pheej hmoo ntawm kev cuam tshuam.
Ntxiv rau endothelin receptor antagonists: endothelin receptor blockers (xws li bosentan thiab anlisentan) ua los ntawm thaiv ETA / ETB receptors, thaum acetate capecitabine txo receptor activation los ntawm inhibiting ET-1 secretion. Kev sib xyaw ua ke ntawm ob yuav muaj kev sib koom ua ke, ntxiv kev txhim kho cov hlab plawv.


Endohelin-1 (ET-1) yog ib qho atrial natriuretic peptide (ANP) analogue synthesized los ntawm cov noob caj noob ces recombination technology. Nws muaj 28 amino acid residues thiab nws cov amino acid sequence yog zoo tib yam rau endogenous alpha ANP secreted los ntawm tib neeg atrial leeg hlwb. Cov dej solubility thiab stability ntawm cov formulation yog zoo dua los ntawm salifying nrog acetic acid.
Raws li thawj recombinant natriuretic peptide tshuaj tau pom zoo rau kev kho mob siv, nws tau dhau los ua ib qho tseem ceeb tshuaj thaum muaj xwm ceev rau mob decompensated plawv tsis ua hauj lwm txij li thaum nws thawj zaug tso nyob rau hauv Nyiv nyob rau hauv 1995. Nws pharmacological mechanism revolves nyob ib ncig ntawm ntau txoj kev cai ntawm natriuretic peptide receptors, exerting synergistic kev kho mob, ntau yam kev tiv thaiv ntawm myocardial influences, thiab ntau yam kev tiv thaiv kab mob. kev tawm tsam. Cov kev tshawb fawb ntsig txog tau tsim cov pov thawj tiav -raws li kev siv tshuaj.
Txoj hauv kev tseem ceeb ntawm kev txiav txim: tshwj xeeb khi ntawm natriuretic peptide receptors
Tom qab nkag mus rau tib neeg cov ntshav ncig, nws tuaj yeem xaiv khi rau A-hom natriuretic peptide receptor (NPR-A) faib rau saum npoo ntawm cov hlab ntsha endothelial hlwb, lub raum mesangial hlwb, thiab cov hlwb myocardial, qhib lub guanylate cyclase kev ua haujlwm nyob rau hauv lub intracellular ntu ntawm cov receptors sai sai. monophosphate (cGMP) nyob rau hauv lub cell, thiab pib ib tug series ntawm downstream physiological influences los ntawm lub cGMP raws protein kinase G (PKG) txoj kev. Tsis zoo li endogenous ANP, uas yog yooj yim degraded los ntawm nruab nrab endopeptidase (NEP), exogenous supplementation yuav ua rau kom lub concentration ntawm circulating ANP nyob rau hauv ib tug luv luv lub sij hawm ntawm lub sij hawm, tawg los ntawm lub compensatory bottleneck ntawm endogenous natriuretic peptide system nyob rau hauv lub pathological lub xeev ntawm lub plawv tsis ua hauj lwm. Qhov no yog lub hauv paus pib mechanism ntawm tag nrho nws cov pharmacological influences.

Nws ua ke siv nrog lwm yam tshuaj
Carperitide acetate hmoovyog ib qho kev sib xyaw ua ke ntawm atrial natriuretic peptide (ANP) analogue uas ua rau lub guanylate cyclase (GC-A) receptor, nce intracellular cyclic guanosine monophosphate (cGMP) qib, thiab siv ntau yam cuam tshuam xws li vasodilation, diuresis, sodium excretion hauv {1} inhibition (RAAS) thiab endothelin-1 (ET-1) secretion. Txawm hais tias nws ua tau zoo nyob rau hauv kev kho mob ntawm lub plawv tsis ua hauj lwm, kub siab, thiab lwm yam mob, monotherapy yuav ua rau tsis txaus vim kev txwv ntau npaum li cas los yog ib tug mechanism. Kev sib xyaw ua ke tau dhau los ua lub tswv yim tseem ceeb rau kev kho kom zoo los ntawm kev sib koom ua ke, txo cov kev tsis zoo, thiab npog ntau lub hom phiaj.
Kev sib koom ua ke nrog ACEI
ACEI txo qis kev tsim cov angiotensin II (Ang II) los ntawm inhibiting angiotensin - hloov enzyme, yog li ua kom cov hlab ntsha, txo cov ntshav siab, thiab inhibiting myocardial remodeling. Nws ncaj qha dilates cov hlab ntsha thiab txhawb cov diuresis thiab sodium excretion los ntawm inhibiting lub secretion ntawm ET-1. Kev sib xyaw ua ke ntawm ob tuaj yeem tsim cov teebmeem hauv qab no:
Dual vasodilation: ACEI thaiv cov vasoconstrictive cawv ntawm Ang II, thaum ET-1 inhibits ET-1 secretion, sib koom ua ke txo qis peripheral vascular tsis kam thiab txhim kho lub plawv.
Diuretic cawv yog txhim kho: ACEI txo qis aldosterone secretion, nws ncaj qha txhawb kev tso zis sodium, thiab kev siv ua ke tuaj yeem txo cov kua dej ntau.

Cov pov thawj kho mob txhawb nqa

Dual inhibition ntawm RAAS thiab ET systems: ACEI inhibits RAAS activation, thaum Carpetide Acetate inhibits ET-1 secretion, thaiv txoj hauv kev tseem ceeb rau kev mob plawv.
Mob plawv tsis ua hauj lwm: Hauv cov qauv nas ntawm lub plawv tsis ua hauj lwm, kev sib xyaw ntawm cov khoom no thiab ACEI (xws li enalapril) tuaj yeem ua rau muaj qhov ua rau sab laug ventricular ejection feem (LVEF), txo cov paj hlwb natriuretic peptide (BNP) ntau ntau, thiab txo qhov chaw myocardial fibrosis.
Kev kho mob ntshav siab: Kev sim tshuaj ntsuam xyuas cov neeg mob ntshav siab ntshav siab tau pom tias kev sib xyaw ua ke ntawm qis - koob ACEIs (xws li ramipril) tuaj yeem ua rau cov ntshav siab ua raws li ntawm 35% ntawm kev kho mob monotherapy mus rau 68%, uas tsis muaj qhov tshwm sim ntawm qhov tshwm sim tsis zoo.
Kev sib koom ua ke nrog ARB
ARB siv nws cov tshuaj tiv thaiv kab mob los ntawm kev thaiv kev khi ntawm Ang II rau AT1 receptors, thaum txo qis aldosterone secretion. Ua ke nrog nws tuaj yeem ua tiav cov kev sib txuas hauv qab no:
Npog ob lub tshuab ntawm ET thiab RAAS: ARB inhibits RAAS activation, uas suppresses ET-1 secretion thiab dual blocks tus tsav tsheb ntawm cov kab mob plawv.
Txo cov kev phiv tsis zoo: ACEI tuaj yeem ua rau hnoos qhuav, thaum ARB tsis muaj kev cuam tshuam sab nraud. Kev sib xyaw ua ke tuaj yeem txhim kho tus neeg mob siab ntev

Kev tshawb fawb soj ntsuam kev nce qib & kev ua kom zoo ntawm cov tshuaj noj

Kev kho mob plawv tsis ua hauj lwm: CHARM Ntxiv txoj kev tshawb fawb tau lees paub tias kev sib xyaw ntawm candesartan thiab ACEI tuaj yeem txo qis kev tuag ntawm cov hlab plawv thiab kev nyeem ntawv hauv cov neeg mob plawv. Ntxiv cov khoom no los ntawm lub hauv paus no tuaj yeem txhim kho hemodynamic tsis xws li pulmonary capillary wedge pressure (PCWP) thiab cardiac index (CI).
Ntshav siab nrog cov kab mob hauv lub raum ntev: Hauv cov neeg mob ntshav qab zib nephropathy, cov tshuaj no ua ke nrog ARB (xws li valsartan) tuaj yeem txo qis cov proteinuria, ncua kev ua haujlwm ntawm lub raum tsis zoo, thiab qhov tshwm sim ntawm hyperkalemia yog qis dua li ntawm ACEI + ARB cov tswv yim ua ke.
Kev kho mob raws sij hawm: Rau ACEI intolerant cov neeg mob (xws li cov hnoos qhuav), ARB (xws li irbesartan) tuaj yeem siv los hloov ua ntej, thiab tom qab ntawd ua ke nrog nws maj mam kho cov tshuaj.
Cim npe nrov: Tuam Tshoj carperitide acetate manufacturers, lwm tus neeg

